Our Pricing

Wegovy Weight Loss Results UK: What the Clinical Trials Show

Published on: June 03, 2026

Understanding wegovy weight loss results uk clinical trial data helps you make informed decisions about semaglutide treatment. At Cured Pharmacy, we provide genuine UK-licensed Wegovy from £79.00 with transparent pricing, free clinical assessment by UK prescribers, and discreet delivery across the UK.

STEP Trial Results: What UK Patients Achieved

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme represents the gold standard evidence for Wegovy's efficacy in the UK and globally. In the landmark STEP 1 trial, participants using 2.4mg semaglutide weekly achieved an average 14.9% body weight reduction over 68 weeks, compared to 2.4% with placebo [1]. This translates to approximately 15.3kg average weight loss for a 100kg individual, subject to individual response and adherence.

STEP 2 specifically examined patients with type 2 diabetes alongside obesity, demonstrating an average 9.6% weight reduction over 68 weeks whilst simultaneously improving glycaemic control [2]. UK prescribers often consider this dual benefit when assessing suitability for patients with both conditions. Importantly, 86.4% of participants in STEP 1 achieved at least 5% weight loss—the threshold NICE recognises as clinically meaningful—whilst 69.1% achieved 10% or greater reduction [1].

The STEP 3 trial incorporated intensive behavioural therapy alongside semaglutide, producing an average 16.0% weight reduction, the highest across the programme [3]. This underscores how Wegovy works most effectively when combined with dietary modification and increased physical activity, as UK prescribers routinely advise during consultations.

How Semaglutide Produces Weight Loss: The Clinical Mechanism

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics a naturally occurring hormone your body produces after eating. It works through three primary pathways: slowing gastric emptying to prolong satiety, reducing appetite signals in the hypothalamus, and improving insulin secretion in response to meals [1]. Unlike appetite suppressants that work solely on the central nervous system, semaglutide addresses multiple physiological pathways simultaneously.

Clinical imaging studies demonstrate that semaglutide reduces activation in brain regions associated with food cravings and reward-seeking behaviour, which may explain why trial participants report reduced preoccupation with food [4]. The once-weekly injection maintains steady therapeutic levels throughout the week, avoiding the peaks and troughs seen with daily medications. UK prescribers typically initiate treatment at 0.25mg weekly, gradually escalating to the maintenance dose of 2.4mg over 16-20 weeks to minimise gastrointestinal side effects whilst the body adjusts.

Dose Escalation Schedule in UK Clinical Practice

The UK-licensed dose escalation protocol begins with 0.25mg weekly for four weeks, increasing to 0.5mg for four weeks, then 1.0mg, 1.7mg, and finally 2.4mg maintenance dose [1]. This gradual titration significantly reduces the incidence of nausea and vomiting—the most commonly reported side effects—compared to starting at higher doses. Your UK prescriber will monitor your tolerance and weight loss progress at each stage, adjusting the timeline if needed based on your individual response.

Long-Term Weight Maintenance: STEP 4 Extension Data

One critical question UK patients ask is whether Wegovy results last beyond the initial trial period. The STEP 4 trial addressed this by having participants achieve weight loss on semaglutide for 20 weeks, then randomising them to either continue treatment or switch to placebo for a further 48 weeks [3]. Those who continued semaglutide maintained their weight loss and lost an additional 7.9% on average, whilst the placebo group regained 6.9% of their body weight.

This data demonstrates that semaglutide works as a long-term weight management medication rather than a short-term fix, requiring ongoing treatment to sustain results. UK prescribers typically discuss this during initial consultations, as patients need realistic expectations about treatment duration. The MHRA licence for Wegovy does not specify a maximum treatment duration, allowing prescribers to continue therapy as long as clinical benefit persists and the patient tolerates it well.

Real-world UK data from early prescribing programmes shows persistence rates of approximately 60-70% at 12 months, with discontinuation primarily due to gastrointestinal side effects or achievement of weight goals [4]. Our superintendent pharmacist Tarun Kumar notes that patients who combine Wegovy with structured dietary changes and regular physical activity typically achieve better long-term outcomes than those relying on medication alone.

Wegovy vs Other Weight Loss Treatments: Comparative Trial Evidence

Head-to-head trials provide valuable context for UK patients comparing treatment options. In the STEP 8 trial, semaglutide 2.4mg produced significantly greater weight loss than liraglutide 3.0mg (Saxenda)—15.8% versus 6.4% at 68 weeks [2]. Both are GLP-1 receptor agonists, but semaglutide's longer half-life allows once-weekly dosing and appears to produce superior weight reduction in clinical trials.

Whilst no direct comparison trials exist between semaglutide and tirzepatide (the dual GIP/GLP-1 agonist), indirect comparisons of their respective trial programmes suggest tirzepatide may produce slightly greater average weight loss—up to 22.5% in SURPASS-3 compared to semaglutide's 14.9% in STEP 1 [1][5]. However, both medications require UK prescription and clinical assessment to determine suitability for individual patients based on medical history, contraindications, and treatment goals.

Oral treatments like orlistat produce more modest results—approximately 3-5% weight loss in clinical trials—but may suit patients who prefer not to use injections or have contraindications to GLP-1 therapies [4]. UK prescribers consider multiple factors including BMI, comorbidities, previous treatment responses, and patient preference when recommending the most appropriate option during your online consultation.

Who Benefits Most from Wegovy in UK Clinical Practice

NICE guidance recommends GLP-1 treatments for weight management in adults with BMI ≥35 kg/m², or ≥30 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnoea. UK prescribers follow these evidence-based thresholds during clinical assessments, though individual circumstances may warrant consideration outside these parameters. Patients with a history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 cannot use Wegovy due to contraindications identified in preclinical studies.

Side Effects Reported in UK Clinical Trials

Understanding the side effect profile helps UK patients prepare for treatment and recognise when to contact their prescriber. In the STEP trials, gastrointestinal effects were most common: nausea (44% vs 17% placebo), diarrhoea (30% vs 16%), vomiting (24% vs 6%), and constipation (24% vs 11%) [1]. These typically emerge during dose escalation and diminish over 4-8 weeks as the body adjusts, though some patients experience persistent symptoms requiring dose reduction or discontinuation.

Serious adverse events occurred in 9.8% of semaglutide participants versus 6.4% on placebo, though most were not attributed to the medication itself [1]. Gallbladder-related events (cholelithiasis and cholecystitis) occurred more frequently with semaglutide—2.6% versus 1.2% placebo—likely related to rapid weight loss rather than direct drug effect [3]. UK prescribers monitor for signs of pancreatitis, though incidence remains low at approximately 0.2% in clinical trials.

Injection site reactions affect fewer than 2% of patients and typically resolve without intervention [2]. Hypoglycaemia risk remains low in patients without diabetes, but those taking concurrent diabetes medications may require dose adjustments of existing therapies. Your UK prescriber will review your complete medication list during assessment to identify and manage potential interactions appropriately.

Starting Wegovy Treatment Through Cured Pharmacy

Beginning your Wegovy journey at Cured Pharmacy involves a straightforward three-step process designed to meet UK regulatory requirements whilst ensuring clinical safety. First, complete our online consultation form, which takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications. Our UK-registered prescribers review every submission individually—there are no automated approvals.

If approved, your prescription is sent electronically to our GPhC-registered pharmacy (registration number 9012511) where our team dispenses genuine UK-licensed Wegovy pens. We dispatch via tracked courier in 100% discreet packaging with no external branding or content description. Most UK addresses receive delivery within 1-2 working days of approval, and we provide full tracking details via email and SMS.

Your prescription includes the starter pack containing 0.25mg and 0.5mg doses for the initial eight-week escalation period. Subsequent prescriptions for higher doses require brief follow-up consultations to assess tolerance, weight loss progress, and any side effects. Our clinical team remains available via phone (+44 116 4646009) throughout your treatment if you have questions or concerns. All ongoing prescriptions qualify for our lowest price guarantee, ensuring you pay competitive rates without hidden fees or subscription charges.

Transparent Pricing and What's Included

Wegovy costs from £79.00 at Cured Pharmacy, representing our commitment to transparent upfront pricing—you see the exact cost before completing your consultation, unlike services that reveal prices only after approval. This includes your UK prescriber consultation at no additional charge, genuine UK-licensed medication, and discreet tracked delivery. We never charge subscription fees, membership costs, or hidden consultation charges that inflate the final price.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
4. Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
5. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual weight loss results may vary and are not guaranteed. Wegovy is a prescription-only medication licensed by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities.